| Scorecard |
|---|
|
2 / 5 Stars
|
|
Lipper
3
2
5
1
1
|
|
Zacks Investment Research
5
(Strong Sell)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
C+
(Hold)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 0.64 | 0.64 |
| Stocks | 66.94 | 66.94 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 32.42 | 32.42 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 02.28.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 02.28.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Roche Holding AG | RHHVF | 23.65 | 8.28 |
| Sanofi | SAN | --- | 5.23 |
| Pfizer Inc | PFE | 16.19 | 5.03 |
| Gilead Sciences Inc | GILD | 36.53 | 4.76 |
| HCA Holdings Inc | HCA | 30.89 | 4.02 |
| Amgen Inc | AMGN | 21.82 | 3.16 |
| Mylan Inc | MYL | 4.55 | 3.12 |
| Merck & Co Inc | MRK | 12.65 | 3.09 |
| Bristol-Myers Squibb Company | BMY | 24.03 | 2.84 |
| Incyte Corp Ltd | INCY | 29.56 | 2.76 |
